Meta-analysis of 10 trials finds intranasal opioids match IV morphine for acute pain
The pooled review of 1164 participants also found no difference in rescue analgesia or in overall, serious, respiratory or hypotensive adverse events.
Key takeaways
- A systematic review in The Journal of Emergency Medicine, indexed November 7, 2026, pooled ten randomized trials with 1164 participants comparing intranasal opioids with IV morphine for acute moderate-to-severe pain.
- Pain score reduction was statistically indistinguishable between the two routes at both 20 and 30 minutes, with low heterogeneity across trials.
- Need for rescue analgesia was the same in both groups, and no significant differences were found in overall, serious, respiratory, hypotensive, gastrointestinal, dizziness or rhinorrhea events.
- Dysgeusia, an altered sense of taste, was the one adverse event the authors described as borderline increased with the intranasal route.
- For crews: the abstract does not name which intranasal opioid, dose or device was used in the trials, nor how many of the ten trials were prehospital.
A systematic review and meta-analysis indexed in PubMed on November 7, 2026, reports that intranasal opioids relieved acute moderate-to-severe pain as well as intravenous morphine at 20 and 30 minutes [1]. The paper appears in The Journal of Emergency Medicine and pooled ten randomized controlled trials with 1164 participants [1].
The authors, led by Fida and colleagues, searched PubMed, Scopus, Web of Science and the Cochrane Library from inception to May 2026 [1]. They included randomized trials in adults or children with acute moderate-to-severe pain treated in emergency department, prehospital, procedural or postoperative settings, as long as the trial directly compared an intranasal opioid with IV morphine [1].
The review found no significant difference between the two routes in the need for rescue analgesia, and no significant difference in overall or serious adverse events [1]. The authors concluded that intranasal opioids provide analgesic efficacy comparable to IV morphine at the two measured time points, with no clear increase in systemic adverse events [1].
What the records show
The primary outcome was the change in pain score from baseline at 20 and 30 minutes [1]. Secondary outcomes were rescue analgesia and adverse events [1]. Results were pooled as standardized mean differences for continuous outcomes and risk ratios for binary outcomes, using random-effects models [1].
At 20 minutes, the pooled standardized mean difference was -0.05 with a 95% confidence interval of -0.24 to 0.14 and a p value of 0.59 [1]. Heterogeneity across trials, measured by I², was 11.94% [1]. At 30 minutes, the standardized mean difference was again -0.05, with a confidence interval of -0.24 to 0.15, a p value of 0.64 and I² of 0.00% [1]. A standardized mean difference near zero with an interval that crosses zero means the trials, taken together, could not distinguish the two routes on pain relief.
Rescue analgesia was required at the same rate in both groups, with a risk ratio of 1.00, a 95% confidence interval of 0.81 to 1.25 and a p value of 0.98 [1].
On safety, the abstract reports no significant differences in overall adverse events, serious adverse events, respiratory complications, hypotension, gastrointestinal events, dizziness or rhinorrhea [1]. The one exception involved taste. According to the abstract, "Dysgeusia was borderline increased." [1]
The abstract frames the clinical rationale this way: intranasal opioids "may provide noninvasive analgesia without delays associated with intravenous (IV) access" [1]. The authors state that the efficacy and safety of that approach relative to IV morphine had remained uncertain before this synthesis [1].
Why it matters for EMS
IV morphine has long served as a reference comparator for acute pain trials, and establishing IV access takes time and skill, particularly in moving ambulances, in children and in patients with difficult veins. The abstract's stated premise is that the intranasal route avoids those delays [1]. This review is the first pooled randomized comparison in the packet to put numbers on that trade-off across emergency, prehospital, procedural and postoperative settings [1].
The finding of no significant difference in respiratory complications or hypotension is directly relevant to field use, because those are the two adverse effects that most concern crews giving opioids without an established line [1]. The abstract does not report the absolute counts of these events, only that the pooled comparison showed no significant difference [1].
The review covered both adults and children [1]. Pediatric pain management is a common area where IV access is hardest to obtain, though the abstract does not break out results by age group [1].
EMS clinicians follow local protocols and medical direction on analgesic route and dosing. This review describes what the trials found; it does not set a standard of care.
What the records do not tell us
The abstract does not identify which intranasal opioid or opioids were studied, what doses were used, or what delivery device administered them [1]. It refers to IN opioids as a class [1]. It does not say how many of the ten trials were prehospital rather than emergency department, procedural or postoperative, so the share of evidence that comes from the field setting is unknown [1].
The abstract does not report results separately for adults and children, and it does not give absolute event counts for any adverse outcome [1]. The size of the dysgeusia increase and its confidence interval are not stated [1]. The abstract also does not describe the risk of bias in the included trials, whether any were blinded, or how pain was scored [1].
The authors themselves note that the pooled trials cannot rule out rare serious harms [1]. In their words, "Larger trials should confirm safety for rare serious events and optimize dosing." [1] The full text of the paper was not available in the records reviewed for this story, so any details beyond the abstract remain unconfirmed.
What to watch
The abstract calls for larger trials to confirm safety for rare serious events and to optimize dosing [1]. No specific follow-up study, date or protocol revision is named in the records.
Questions readers ask
Are intranasal opioids as effective as IV morphine for acute pain?
A 2026 meta-analysis in The Journal of Emergency Medicine pooled ten randomized trials with 1164 participants and found no significant difference in pain score reduction between intranasal opioids and IV morphine at 20 or 30 minutes. Rescue analgesia rates were also the same.
Are intranasal opioids safer than IV morphine?
The review found no significant differences in overall adverse events, serious adverse events, respiratory complications, hypotension, gastrointestinal events, dizziness or rhinorrhea. Dysgeusia, or altered taste, was borderline increased with the intranasal route. The authors said larger trials are needed to confirm safety for rare serious events.
Which intranasal opioid did the meta-analysis study?
The published abstract does not name the specific intranasal opioids, doses or delivery devices used in the ten included trials. It describes the intervention only as intranasal opioids compared with IV morphine.
Did the review include prehospital EMS trials?
Eligible trials included emergency, prehospital, procedural and postoperative settings in adults or children. The abstract does not state how many of the ten trials were conducted in the prehospital setting.
Sources
- Fida L et al., Comparative Efficacy and Safety of Intranasal Opioids vs. Intravenous Morphine for Acute Moderate-to-Severe Pain, The Journal of Emergency Medicine (PubMed) (2026-11-07). pubmed.ncbi.nlm.nih.gov/42994114/
This is news, not medical advice. EMS clinicians: follow your local protocols and medical direction.
